Who is sponsoring NCT00476853?

NCT00476853 is sponsored by The HIV Netherlands Australia Thailand Research Collaboration.

What condition does NCT00476853 study?

NCT00476853 studies HIV Infections, Tuberculosis.

What drugs are being tested in NCT00476853?

Interventions: HAART containing nevirapine.

What is the status of NCT00476853?

NCT00476853 is currently COMPLETED.

Last reviewed 2020-07-15 · How we verify

A 48 Week, Randomized, Open-label, 2 Arm Study to Compare the Efficacy, Safety and Tolerability of HAART Containing Nevirapine 400mg/Day Versus Nevirapine 600 mg/Day in HIV-1 Infected Patients Started at 2-6 Weeks After Initiating Rifampin Containing Antituberculous Therapy

NCT00476853 Phase 2 COMPLETED

A 48 week, randomized, open-label, two arm study to compare the efficacy, safety and tolerability of HAART containing nevirapine 400 mg/day versus nevirapine 600 mg/day in HIV-1 infected patients started at 2-6 weeks after initiating rifampicin containing antituberculosis therapy.

Details

Lead sponsor	The HIV Netherlands Australia Thailand Research Collaboration
Phase	Phase 2
Status	COMPLETED
Enrolment	42
Start date	2005-10
Completion	2009-12

Conditions

HIV Infections
Tuberculosis

Interventions

HAART containing nevirapine

Primary outcomes

Efficacy of nevirapine based HAART 400 mg/day versus 600 mg/day on HIV-1 load as measured by HIV-1 RNA quantification in plasma — 48 weeks

Countries

Thailand